| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
- | - | - | 2,814 | - | - | - |
Grant revenue | ||||||
- | - | - | 663 | - | - | - |
Revenue: | ||||||
Total revenue | ||||||
4,461 | 8,386 | 4,003 | - | - | - | - |
Total revenue | ||||||
- | - | - | 3,477 | 2,538 | 4,320 | 4,316 |
Operating expenses: | ||||||
Cost of revenue | ||||||
- | - | - | - | 2,472 | 3,366 | 2,778 |
Research and development | ||||||
34,794 | 30,421 | 19,623 | 13,692 | 1,002 | 347 | 225 |
Selling and marketing | ||||||
- | - | - | - | 2,559 | 717 | 349 |
General and administrative | ||||||
11,646 | 11,049 | 10,912 | 6,772 | 7,692 | 6,857 | 1,411 |
Exit costs | ||||||
- | - | - | - | 0 | - | - |
Loss on impairment of assets | ||||||
- | - | - | - | 0 | - | - |
Gain on legal settlement | ||||||
- | - | - | - | - | 100 | 250 |
Total operating expenses | ||||||
- | - | - | - | 13,725 | 11,187 | - |
Total operating expenses | ||||||
46,440 | 41,470 | 30,535 | 20,464 | - | - | 4,513 |
Loss from operations | ||||||
-41,979 | -33,084 | -26,532 | -16,987 | -11,187 | -6,867 | -197 |
Other income (expense): | ||||||
Interest and other income | ||||||
941 | 1,254 | 403 | 39 | - | - | - |
Interest and other expense | ||||||
835 | 873 | 383 | 326 | - | - | - |
Interest expense | ||||||
- | - | - | - | 141 | 1,023 | 1,963 |
Loss on extinguishment of debt | ||||||
- | - | - | - | 0 | - | - |
Total other expense | ||||||
- | - | - | - | 141 | - | - |
Net Income (Loss) Attributable to Parent | ||||||
-41,873 | -32,703 | -26,512 | -17,274 | -11,328 | -7,890 | -2,160 |
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax | ||||||
3 | -3 | 0 | - | - | - | - |
Comprehensive loss | ||||||
-41,870 | -32,706 | -26,512 | - | - | - | - |
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | 5 | 49 | - | - | - |
Dividend to member unit holder of Myeloma Health LLC | ||||||
- | - | - | - | - | - | 285 |
Net loss | ||||||
-41,873 | -32,703 | -26,517 | -17,323 | - | - | -2,445 |
Net loss per share, basic and diluted (in dollars per share) | ||||||
-1.34 | -1.10 | -1.38 | -28.21 | -21.02 | -52.50 | -12.23 |
Weighted-average shares used to compute basic and diluted net loss per share (in shares) | ||||||
31,336 | 29,600 | 19,244 | 614 | 539 | 150 | 200 |
Collaboration revenue | ||||||
Total revenue | ||||||
4,308 | 7,373 | 3,097 | - | - | - | - |
Grant revenue | ||||||
Total revenue | ||||||
153 | 1,013 | 906 | - | - | - | - |